Ovoca Bio Plc (OVB) Euro 0.125
Share news, reports & tips
29 July 2022 16:00
(Sharecast News) - Women's health-focussed biopharmaceutical company Ovoca Bio announced the successful completion of participant enrollment in a phase 2 dose-ranging study assessing...
29 January 2021 11:15
(Sharecast News) - Biopharmaceutical company Ovoca Bio said on Friday that the first patient has been enrolled in a phase 2 dose-ranging study assessing 'BP-101', which it described as a novel...
9 October 2020 15:47
(Sharecast News) - Women's health-focussed biopharmaceuticals company Ovoca Bio announced the appointment of Christopher Wiltshire as its chief business officer and executive director of the board on...
2 October 2020 10:10
(Sharecast News) - Biopharmaceutical company Ovoca Bio updated shareholders on Friday on its marketing authorisation application for BP-101, a novel synthetic peptide administered through a nasal spray, that...
16 September 2019 11:33
(Sharecast News) - Biopharmaceutical firm Ovoca Bio narrowed losses slightly in the first half of its trading year, while focus remained firmly on its continued development of a treatment for female sexual...
Company announcements Announcements
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2022. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.